ClinicalTrials.gov
ClinicalTrials.gov Menu

Multimodal Investigation of the Neuroprotective Effects of Resveratrol (MINER) (MINER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03665740
Recruitment Status : Recruiting
First Posted : September 11, 2018
Last Update Posted : September 11, 2018
Sponsor:
Collaborators:
Texas A&M University
Baylor University
K. R. Love Quantitative Consulting and Collaboration
Information provided by (Responsible Party):
Dena Davidson, VISN 17 Center of Excellence

Brief Summary:
Since their return from military service in the 1990-1991 Gulf War, many Veterans have been affected by debilitating symptoms that are not easily explained. A leading hypothesis states that the combination of exposure to toxic chemicals and environmental stressors are responsible for a cluster of debilitating symptoms known as Gulf War Illness (GWI). Research has found that over-the-counter antioxidant supplements such as resveratrol may reverse the damage that causes these debilitating symptoms. Resveratrol is a nutrient found abundantly in the skin of red grapes that is known to have robust antioxidant and anti-inflammatory properties. The investigators predict that resveratrol treatment will improve memory issues, difficulties with thinking and mood problems in Veterans with GWI and that resveratrol will do so with minimal risk.

Condition or disease Intervention/treatment Phase
Gulf War Illness Drug: Resveratrol Phase 2

Detailed Description:

A randomized controlled trial is proposed that will employ well-validated instruments and state-of-the-art techniques to assess improvements in cognitive functioning, functional status, mood, hippocampal neurogenesis and functional connectivity as well as anti-inflammatory and antioxidant effects of treatment with resveratrol. Design: The proposed study will be an intent-to-treat outpatient, randomized, double-blind, clinical trial of 93 Veterans who meet the Centers for Disease Control and Prevention and Kansas case definitions for GWI.

The study involves a comparison of resveratrol at a dose of 2000 mg and placebo. All doses will be administered orally once or twice daily. Doses of resveratrol at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the resveratrol, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment. Morning dosing will be taken with or before breakfast. Evening dosing will be taken with or before dinner.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 68 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized Double-blind Placebo controlled, intent-to-treat
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: double blind
Primary Purpose: Treatment
Official Title: A Pilot RCT on the Effect of Resveratrol on Mood, Memory Deficits, Hippocampal Inflammation and Neurogenesis in Veterans With Gulf War Illness
Actual Study Start Date : August 1, 2018
Estimated Primary Completion Date : August 31, 2022
Estimated Study Completion Date : August 31, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Resveratrol

Arm Intervention/treatment
Experimental: Resveratrol
Doses of resveratrol at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the resveratrol, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment.
Drug: Resveratrol
resveratrol is an OTC supplement

Placebo Comparator: Placebo
Doses of placebo at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the placebo, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment
Drug: Resveratrol
resveratrol is an OTC supplement




Primary Outcome Measures :
  1. Change from baseline in Cognitive Function [ Time Frame: Baseline & Post (week 26) ]
    CVLT-II: measure of cognitive functioning and memory

  2. Change from baseline in Mood [ Time Frame: Baseline, Mid (week 13) and Post (week 26) ]
    Beck Depression Inventory II

  3. Change from baseline in Daily Functioning [ Time Frame: Baseline and Post (week 26) ]
    WHODAS 2.0: measure of disability and global health


Secondary Outcome Measures :
  1. Change from baseline in Structural MRI Scans [ Time Frame: Baseline & Post (Week 26) ]
    Structural MRI scanning of hippocampus

  2. Change from baseline in Diffusion Tensor Imaging [ Time Frame: Baseline & Post (Week 26) ]
    A diffusion tensor imaging scan of hippocampus


Other Outcome Measures:
  1. Change from baseline in Pro-inflammatory cytokines [ Time Frame: Baseline & Post (Week 26) ]
    IL-1β; TNF-α; IL-6; IL-1α; Interferon-Y; G-CSF/CSF3; GM_CSF/CSF2; IL-8; IP-10; RANTES; Resistin; PAI-1; IL-12; IL-13; Eotaxin-3; MCP-1; MIP-1α; IL-2; Leptin; Adiponectin; IL-17α; IL-4; IL10



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   44 Years to 68 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Served on active military duty and deployed to the Persian Gulf region August 1990 - July 1991;
  2. English speaking and able to understand the consent form and study questionnaires;
  3. Willing and able to be randomized to treatment and to commit to a 26-week study;
  4. Men and women between the ages of 44 to 68 (the number of 1990-1991 Gulf War Veterans who are older than 68 dramatically decreases because many of those with GWI have died prematurely);
  5. Meet the Kansas case definition for the diagnosis of GWI as well as the more inclusive CDC definition
  6. Stabilization on any psychiatric medication (≥3 months on selective serotonin reuptake inhibitor or monoamine oxidase inhibitor, ≥1 month on anxiolytic or beta-blockers);
  7. Female subjects of childbearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test and agree to use reliable method of birth control (for example, oral contraceptives or Norplant; a reliable barrier method of birth control [diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam]; intrauterine devices; partner with vasectomy; or abstinence) during the study. Note that this inclusion criterion applies only to females of childbearing potential. Females of childbearing potential are defined as women not surgically sterilized and between menarche and 2 years post-menopause.

Exclusion Criteria:

  1. Unstable or poorly controlled diabetes type II (HbA1C >9.0);
  2. Cancer;
  3. Lifetime diagnosis of schizophrenia or bipolar disorder or a history of psychiatric hospitalization for, or current diagnosis (i.e., the past 6 months) of substance dependence;
  4. Major depressive disorder or posttraumatic stress disorder requiring hospitalization;
  5. Significant CNS disease including TIAs or stroke, dementia, syncopal episodes, severe head trauma, multiple sclerosis;
  6. Serious or advanced heart disease or clinically relevant abnormal electrocardiogram (ECG) or postural hypotension;
  7. Untreated sleep apnea or body mass index (BMI) placing patients at risk for undiagnosed sleep apnea (BMI≥35 kg/m2);
  8. Subjects with renal insufficiency or chronic renal disease defined by national Kidney Foundation Disease Outcome Quality Initiative criteria (2000) with a GFR less than or equal to 90 mL/min/1.73m2. Laboratory monitoring of CR and Bun and eGFR will be obtained at baseline and prior to each titration and at study end or early termination. If Cr and Bun increase above upper limit of normal and eGFR drops to <45 or more than 35% the study drug will be discontinued and a nephrology consult will be ordered;
  9. Liver enzymes >3 times normal on 3 consecutive laboratory tests; evidence of significant hepatocellular injury as evidenced by elevated serum levels of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 times the upper limit of normal (ULN); total or indirect bilirubin greater than 1.2 x ULN; alkaline phosphatase greater than 1.5 x ULN; prothrombin time (PT) as INR greater than 2.4 x ULN; or albumin less than 1 times the lower limit of normal (LLN) at baseline. Resveratrol is only anticipated to affect LFTs indirectly, by slowing statin metabolism. Persistent significant elevation of amino transferases are defined as >3x normal of normal upper limit on 2 consecutive measurements. Under the conditions of high dose statin therapy, it is typically addressed by temporarily stopping statin administration, then slowly titrating the dose back up under careful observation. Failure to reduce aminotransferase levels after the temporary cessation of statins (and a third LFT measurement is taken) would necessitate cessation of resveratrol treatment.
  10. Use of cytochrome P450 3A4 substrates with high risk of toxicity (e.g., terfenadine, cisapride, astemizole, disopyramide, amiodarone, dronedarone, colchicine, cyclosporine, quinidine, pimozide, cisapride, amlodipine, felodipine, nicardipine, nifedipine, nisoldipine, nitrendipin, nimodipine and verapamil);
  11. Use of blood thinners (e.g., Coumadin);
  12. Use of resveratrol-containing supplements.

    Participation in the scanning portion of the study is not required to participate in the clinical trial. Subjects who are interested in the scanning study will be asked to sign a second consent and will be screened for MRI-specific exclusion criteria. The additional exclusion criteria for participating in the MRI portion are listed below.

  13. General medical conditions that would prevent the participant from completing MRI scanning (active seizure disorder, dementia, active back or muscle spasms);
  14. Positive MRI safety screen for metal or history of penetrating head or eye wound without subsequent radiological evidence that the wound is metal-free;
  15. Participants that are (were) welders or that have had metal surgically removed from their eyes without radiological evidence that the wound is metal-free;
  16. MRI quality problems (tremors, significant claustrophobia);
  17. Shrapnel or other metal embedded in the body;
  18. Implanted orthopedic devices (e.g., metal rods, plates or screws but excluding nonferrous material);
  19. Implanted metal devices or prosthetics, or mechanical implants (e.g., pacemakers, electrical implants, cochlear implants);
  20. Implanted contraceptive devices (excluding those made of nonferrous material);
  21. Outside devices made of metal (e.g., neck braces, surgical staples, or artificial limbs), or non-removable dentures, braces or other metal orthodontics;
  22. Tattoos not done professionally or non-removable body piercings.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03665740


Contacts
Contact: Tabitha Alverio, M.A. 254.297.3259 Tabitha.Alverio@va.gov
Contact: Laura Constable, M.A. 254.297.3954 Laura.Constable@va.gov

Locations
United States, Texas
VISN 17 Center of Excellence for Research on Returning War Veterans Recruiting
Waco, Texas, United States, 76711
Contact: Tabitha Alverio, M.A.    254-297-3259    Tabitha.Alverio@va.gov   
Contact: Laura Constable, Ph.D.    254.297.3954    Laura.Constable@va.gov   
Principal Investigator: Dena Davidson, Ph.D.         
Sub-Investigator: Bryann DeBeer, Ph.D.         
Sub-Investigator: Geoffrey May, MD         
Sub-Investigator: Steven Nelson, Ph.D.         
Sponsors and Collaborators
VISN 17 Center of Excellence
Texas A&M University
Baylor University
K. R. Love Quantitative Consulting and Collaboration
Investigators
Principal Investigator: Dena Davidson, Ph.D. VISN 17 Center of Excellence

Additional Information:
Responsible Party: Dena Davidson, Director of Research, VISN 17 Center of Excellence
ClinicalTrials.gov Identifier: NCT03665740     History of Changes
Other Study ID Numbers: GW160050
First Posted: September 11, 2018    Key Record Dates
Last Update Posted: September 11, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Dena Davidson, VISN 17 Center of Excellence:
Gulf War Illness
Chronic Multisymptom Illness
Antioxidants
Resveratrol
Gulf War Syndrome

Additional relevant MeSH terms:
Resveratrol
Platelet Aggregation Inhibitors
Neuroprotective Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Enzyme Inhibitors
Antimutagenic Agents
Anticarcinogenic Agents